SCHEMBL176249

SCHEMBL176249

COc1ccccc1-c1nccc(OC)c1B(O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.47
ENPP2 Q13822 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
HPGD P15428 2/20 0.44
ORAI1 Q96D31 1/20 0.43
ORAI2 Q96SN7 1/20 0.43
ORAI3 Q9BRQ5 1/20 0.43
UGCG Q16739 5/20 0.43
CYP1A2 P05177 2/20 0.42
CYP3A4 P08684 2/20 0.42
CYP2D6 P10635 2/20 0.42
KDM4E B2RXH2 3/20 0.42
LMNA P02545 2/20 0.42
GAA P10253 1/20 0.42
ADORA2A P29274 2/20 0.39
APP P05067 1/20 0.39
MAOA P21397 1/20 0.39
ADORA1 P30542 1/20 0.38
CCNB2 O95067 1/20 0.38
CDK1 P06493 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28649079 0.79 ENPP2 (0.55) ALDH1A1ENPP2SMN1; SMN2HPGDORAI1
SCHEMBL28044194 0.74 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2HPGDUGCGCYP1A2
SCHEMBL2657700 0.73 ENPP2 (0.39) ENPP2ORAI1ORAI2ORAI3CDK5
SCHEMBL29956241 0.73 ENPP2 (0.39) ALDH1A1ENPP2SMN1; SMN2HPGDORAI1
SCHEMBL5039573 0.73 ENPP2 (0.39) ALDH1A1ENPP2SMN1; SMN2HPGDORAI1
SCHEMBL4702995 0.73 ENPP2 (0.39) ALDH1A1ENPP2ORAI1ORAI2ORAI3
SCHEMBL27526791 0.73 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2HPGDUGCGCYP1A2
SCHEMBL29953746 0.71 ENPP2 (0.38) ALDH1A1ENPP2SMN1; SMN2ORAI1ORAI2
SCHEMBL31016790 0.71 ENPP2 (0.38) ALDH1A1ENPP2ORAI1ORAI2ORAI3
SCHEMBL203282 0.71 ENPP2 (0.60) ALDH1A1ENPP2SMN1; SMN2HPGDORAI1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120059032-A1 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES EFFECTIVE AS ANTIGLIOMA AGENTS, METHODS OF MAKING, AND THEIR USE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2012-03-08 US disclosed
WO-2011022518-A1 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES EFFECTIVE AS ANTIGLIOMA AGENTS, METHODS OF MAKING, AND THEIR USE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2011-02-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059032-A1 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES EFFECTIVE AS ANTIGLIOMA AGENTS, METHODS OF MAKING, AND THEIR USE BAD, BAK1, CASP3 ALDH1A1 2394/4885ENPP2 1781/4885SMN1; SMN2 1427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.